NFL Biosciences collaborates with the CEA

Tobacco addiction: NFL Biosciences collaborates with the CEA by entrusting it with a study of the mechanism of action of its drug candidate NFL-101

NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of dependencies and addictions, announcement the implementation of ae study, with the Central commission of nuclear energy and to Energies Alternatives (ECA), on the mechanism of action of its drug candidate NFL-101.

NFL-Biosciences will use the CEA’s molecular imaging resources to better understand the mechanism of action of NFL 101. NFL-101 derives from a subcutaneous desensitization treatment which had been developed by the Institut Pasteur against allergies to tobacco among tobacco factory workers. Used without prescription by a French doctor on more than 10,000 smokers, the repositioned Institut Pasteur extract had shown promising results which were supported by a retrospective study. NFL-101 is a standardized version for pharmaceutical use.

The study will be conducted by the CEA’s Pharmacological Neuroimaging team. It will consist of following, by positron emission tomographic (PET) imaging, the changes in brain function associated with the development of tobacco dependence in mice in order to highlight the central effects of NFL-101 treatment in this context. The planned duration of this study is 9 months.

Bruno Lafont, Deputy CEO and co-founder of NFL Biosciences:  » This research is intended to better understand how NFL-101 may act on tobacco dependence when in clinical practice it is only administered once or twice and than current treatments have to be daily for 3 months, with even in the case of varenicline (Champix®, Chantix®) three then twice a day ».

For Nicolas Tournier, pharmacologist, radiopharmacist and head of the Pharmacological Neuroimaging team at the CEA: “ This project takes full advantage of the potential of molecular imaging to highlight the effects of drugs on the brain, particularly in the context of treatment of tobacco addiction. The non-invasive and translational nature of the imaging techniques used might to permit to highlight ath activity basede on a communication betweenthe immune system and the central nervous system, differente modes of action current smoking cessation drugs that targetslow nicotinic receptors. »

The results, which may be the subject of a joint scientific publication, will complete the CESTO II and PRECESTO clinical studies with a view to increasing the overall attractiveness of NFL-101 to pharmaceutical laboratories which may be interested in taking out licences.

To About NFL Biosciences

NFL Biosciences is a biopharmaceutical company based in the Montpellier region whose most advanced botanical drug candidate is a smoking cessation aid. Called NFL-101, this natural product, extracted from standardized tobacco leaves and devoid of nicotine, is protected by two families of patents. NFL Biosciences intends to offer smokers who wish to quit a natural, safe, effective long-term alternative, with short and personalized administration. Beyond NFL-101, NFL Biosciences has plans to develop botanical drugs for the treatment of cannabis use disorders and alcoholism. NFL Biosciences shares are listed on Euronext Growth Paris (FR0014003XT0 – ALNFL). More information on www.nflbiosciences.com

Contacts

Bruno Lafont – info@nflbiosciences.com – 04 11 93 76 67

Calyptus Agency – nflbio@calyptus.net – 01 53 65 68 68

• 20230110 – NFLBioscience_CP_CEA_EN – FINAL VERSION